english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2024 > Prescrire Drug Awards for 2024 > Prescrire Drug Awards for 2024 > Prescrire's ratings for new drugs and new indications

The Prescrire Awards for 2024

Prescrire Drug Awards for 2024

The Prescrire Drug Awards for 2024
Prescrire's ratings for new drugs and new indications

PRESCRIRE'S RATINGS

Our ratings indicate whether a product represents a therapeutic advance in the relevant clinical situation. We consider not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing treatments. Note that the relative value of new products can vary from one country to another.
 

Bravo

BRAVO

The product is a major therapeutic advance in an area where previously no treatment was available.

A Real Advance

A REAL ADVANCE

The product is an important therapeutic advance but has certain limitations.

Offers an advantage

OFFERS AN ADVANTAGE

The product has some value but does not fundamentally change current therapeutic practice.

Possibly helpful

POSSIBLY HELPFUL

The product has minimal additional value, and should not change prescribing habits except in rare circumstances.

Nothing new

NOTHING NEW

The product has not been shown to represent a therapeutic advance.

Not acceptable

NOT ACCEPTABLE

Product without evident benefit but with potential or real disadvantages.
 

Judgement reserved

JUDGEMENT RESERVED

The editors postpone their rating until better data and a more thorough evaluation of the product are available.

 

Le Palmarès de l'information
 The Prescrire Drug Awards for 2024


Download the full article:

Télécharger
 "The Prescrire Awards for 2024" Prescrire Int 2025; 34 (270): 136-139. FREE.

 

Back to "The Prescrire Awards for 2024"

©Prescrire May 2025      

Filet

Enjoy full access to Prescrire International, and support independent medical information